Ajit Johnson Nirmal is a Research Fellow at DFCI and HMS, working under the mentorship of Prof. David Weinstock and Prof. Peter Sorger. He works on multi-dimensional characterization of minimal residual disease (MRD’s) in lymphoma to delineate their genetic, transcriptional, spatial and biophysical attributes at a single-cell level to identify MRD-specific vulnerabilities, thereby to shift the paradigm of lymphoma treatment from maximum tumor debulking to cure. The study also catalyzes advances across other cancer types by providing the necessary platform technologies, resources and computational tools. The ultimate impact is a paradigm shift toward biomarker-based approaches for converting deep remissions of lymphomas into cures.
Ajit recieved a PhD in cancer gentics and genomics from the University of Edinburgh. He used large cancer datasets to identify, characterize and model immune system across different tumour types. He developed ImSig, a network-based computational framework that facilitates the characterization of immune cells within the tumor microenvironment.
- Department of Medical Oncology, Dana-Farber Cancer Institute
- Laboratory of Systems Pharmacology, Harvard Medical School
- The Broad Institute